Incorporating More Science Into Cancer Dose-Response Extrapolations

  • Robert L. SielkenJr.
Part of the Advances in Risk Analysis book series (AIRA, volume 6)


Dose-response models can be an important part of the quantitative cancer risk assessments supporting risk management and regulatory decision making. Current dose-response models have limited biological rationale and tend to greatly over-simplify the carcinogenic process. While complete understanding of carcinogenic mechanisms and all-encompassing models are still beyond our grasp, new approaches to dose-response modeling can provide opportunities for these models to incorporate more scientific information. A new family of dose-response models called the Individualized Response Models is introduced and shown to provide such opportunities. The models allow for the use of more biologically relevant dose scales such as those provided by physiologically-based pharmacokinetic models of the absorption, delivery, metabolism, and elimination of a chemical as well as research on cell turnover rates, repair mechanisms, and immune system responses even if these phenomena are age-dependent. Since different individuals may have different physiological behavior and different background exposures, allowances are made for modeling populations with distributions of individual susceptibilities and background doses. The inclusion of time in the Individualized Response Models allows them to incorporate dose levels, susceptibilities, and background exposures which are not constant over time and also reflect age-dependent changes in the number of target cells and the effects of cell proliferation on the number of intermediate cells in a multistage process. Since the improved dose scales and other modeling extensions are related to physical phenomena, their nature, interrelationship, and functional dependence on dose, time, and age can frequently be investigated through independent scientific research prior to the fitting of the chronic dose-response data.


Individual variation susceptibility dose-response modeling biologically effective dose physiologically-based pharmacokinetic models biological models 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Armitage, P., and Doll, R., 1961, Stochastic Models for Carcinogenesis, in Proceedings of the Fourth Berkeley Symposium on Mathematical Statistics and Probability, J. Neyman, Ed., Vol. 4, p. 19, University of California Press, Berkeley and Los Angeles.Google Scholar
  2. Cleaver, J. E., 1984, Chairman’s Comments: Variations in Individual Susceptibility to Genotoxic Agents, in Banbury Report 16: Genetic Variability in Responses to Chemical Exposure, G. S. Omenn and H. V. Gelboin, Eds., p. 225, Cold Spring Harbor Laboratory.Google Scholar
  3. Harris, C. C., 1983, Concluding Remarks: Role of Carcinogens, Cocarcinogens, and Host Factors in Cancer Risk, in Human Carcinogenesis, C. C. Harris and H. N. Autrup, Eds., Ch. 38, p. 941, Academic Press.Google Scholar
  4. Moolgavkar, S. H., and Venzon, D. J., 1979, Two-Event Models for Carcinogenesis: Incidence Curves for Childhood and Adult Tumors, Math. Biosci. 47: 55.CrossRefGoogle Scholar
  5. Moolgavkar, S. H., and Knudson, A. G., 1981, Mutation and Cancer: A Model for Human Carcinogenesis, JNCI 66: 1037.PubMedGoogle Scholar
  6. Omenn, G. S., 1984, Risk Assessment, Pharmacogenetics, and Ecogenetics, in Banbury Report 16: Genetic Variability in Responses to Chemical Exposure, G. S. Omenn and H. V. Gelboin, Eds., p. 3., Cold Spring Harbor Laboratory.Google Scholar
  7. Thorslund, T. W., Brown, C. C., and Chamley, G., 1987, Biologically Motivated Cancer Risk Models, Risk Analysis 7: 109.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Robert L. SielkenJr.
    • 1
  1. 1.Sielken, Inc.BryanUSA

Personalised recommendations